Comment

APAC early-stage innovators raise one-third less VC funds than US players

Biotechs based in APAC have historically focused on generics and manufacturing, but are shifting towards innovative developments, according to GlobalData.

Credit: Shutterstock/BongkarnGraphic

Venture financing for early-stage innovator drugs for biotech companies based in the Asia-Pacific (APAC) region between 2018 to 2022 received three times less funding, at $23bn, than their US counterparts, at $72bn, according to GlobalData’s Pharma Intelligence Centre Deals Database.

Although both regions experienced a surge in deal value and volume for early-stage venture financing for innovator drugs from 2020 to 2021, inflation and geopolitical factors such as the Russia-Ukraine war impacted market volatility. This caused investors to be more discerning, which resulted in a decrease in investments last year.

The Biotech Showcase: Asia Pacific Showcase, held on 10 January this year, included APAC and US investors discussing the biotech investing landscape at a panel titled 'BioPharma Investment Trends in the Asia Pacific Region: What you Need to Know'.

Rare earths are are also important for the permanent magnet synchronous generator technologies used in onshore and offshore wind turbines

On the critical end of the scale, lutetium makes up the essential part of the detectors used in position emission tomographs, which are devices used in hospitals that image cancers. Without lutetium, patients would need a lot more radiation to get useful images.

Rare earths are are also important for the permanent magnet synchronous generator technologies used in onshore and offshore wind turbines. They are also vital components of defence systems key to the US military, including communications equipment, precision-guided weapons, night-vision goggles and stealth technology.

Chinese dominance and Western complacence

According to GlobalData’s Pharma Intelligence Centre Deals Database, the total deal value of early-stage innovator drug venture financing for US biotechs grew 70% to $24.4bn from 2020 to 2021, at a 24% increase in deal volume. Early-stage innovator drug venture funding for APAC biotech had a 78% growth in total deal value to $9.4bn, with a 68% increase in deal volume for the same period (Figure 1). Biotechs based in APAC and the US reported a decrease in deal volume of 32% and 33%, respectively, and total deal value of 59% and 44%, respectively, in 2022. Notably, APAC’s venture financing rounds achieved lower valuations. 

According to Vivian Lee, managing director at Aqua Partners, biotechs based in APAC have historically focused on generics and manufacturing, but are shifting towards innovative developments. Panelist Elizabeth Kelly, principal at Pappas Capital, predicted 'a big wave of disruption in new technology that is going to come out of these regions in the markets'. Kelly noted that the challenges posed by the Covid-19 pandemic in China 'have led to an influx of capital and innovation in Singapore from domestic and other markets', making it an attractive option for driving innovation in other APAC countries.

Credit: Getty Images/Catherine Falls Commercial

Meanwhile, China continues to catch up to Western venture financing, as shown in recent funding rounds. Neumora Therapeutics, based in the US, secured $400m in Series A financing for their neurodegenerative disorder drugs in 2021. Hangzhou DAC Biotech, based in China, raised $155.4m in Series C financing in the same year to support the development of their oncology drugs, highlighting smaller investment funding in China compared to the US.

Eisai’s director of corporate venture investment, Ryutaro Adachi, highlights successful transactions between Japanese start-ups and foreign pharmaceutical investors. This includes new biotech company Aculys Pharma securing $22.9m in Series B financing in 2022 to support the development and commercialisation of its central nervous system drugs. As a corporate venture, Eisai invests in 'seed, early and pre-clinical platform technologies' and seeks out potential start-ups to create 'future synergy' with the company.

Although the US continues to lead the biotech venture financing raised for innovator drugs, biotechs based in APAC are making strides in innovative developments to secure funding. Despite market volatility affecting both regions, growing interest in APAC’s innovative technologies from Western pharmaceutical companies could provide future opportunities in this space.

Go to article: Home | CoverGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: ControlantGo to article: SyntegonGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: CfPIEGo to article: In DepthGo to article: Dawn of a new indication: How to study drugs for aging Go to article: Cleanroom tech tackles environmental impact of consumables Go to article: Tapping into digital therapeutics to improve neurological outcomes Go to article: CMO Moves: Regulatory catalysts for drug manufacturing – March Go to article: Ethics of ultra-rare disease drug development and expanded accessGo to article: APAC early-stage innovators raise one-third less VC funds than US players Go to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: Bio Image Systems Inc.Go to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: the transformative power of cloud Go to article: An introduction to cloud computingGo to article: A history of cloud computingGo to article: The impact of cloud computing on the pharmaceutical industry Go to article: Applications of cloud computing in the pharmaceutical industry Go to article: Latest news: cloud computing in pharma Go to article: Q&A with GlobalData thematic analystGo to article: Is RFID the future of smart labelling?Go to article: Cloud robotics labs are accelerating drug discovery and development Go to article: Leading pharma companies in the cloud computing theme Go to article: Deal activity related to cloud in the pharmaceutical industry since 2020 Go to article: Cloud hiring trends in the global pharmaceutical industry since 2020 Go to article: Cloud patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of cloud in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: HOF SonderanlagenbauGo to article: Thermo Fisher ScientificGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue